AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
+0.34 (0.47%)
After Hours: 72.95 +0.01 (0.01%)
Oct 31, 5:17PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 72.30 - 73.13
52 week 52.08 - 82.68
Open 72.59
Vol / Avg. 2.51M/2.35M
Mkt cap 90.97B
P/E 45.44
Div/yield 0.90/3.84
EPS 1.61
Shares 1.26B
Beta 0.55
Inst. own 8%
Nov 18, 2014
AstraZeneca PLC Investor Day Add to calendar
Nov 6, 2014
Q3 2014 AstraZeneca PLC Earnings Call - 7:00AM EST - Add to calendar
Nov 6, 2014
Q3 2014 AstraZeneca PLC Earnings Release - 2:00AM EST - Add to calendar
Sep 28, 2014
AstraZeneca PLC European Society for Medical Oncology (ESMO) 2014 Analysts and Investors Briefing
Sep 23, 2014
AstraZeneca PLC at EBD Group BioPharm America
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 12.35% 10.00%
Operating margin 17.18% 14.44%
EBITD margin - 31.92%
Return on average assets 5.42% 4.70%
Return on average equity 14.69% 10.89%
Employees 51,500 -
CDP Score - 85 B


2 Kingdom Street, Paddington
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 55
Bio & Compensation  - Reuters
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 61
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Caroline Hempstead Interim Executive Vice-President, Human Resources & Corporate Affairs
Bio & Compensation  - Reuters
Paul Hudson Executive Vice President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Briggs Morrison Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters
David Smith Executive Vice President - Operations and Information Services
Bio & Compensation  - Reuters